Sweetgreen Slashes FY26 Same-Store Sales Outlook to 7-8% Decline as Cyclosporiasis Outbreak Hits Traffic; Founders Adopt 10b5-1 Plans
SG is trading near its 52-week low of $4.49 (11% above the low).
Summary
Sweetgreen cut its FY26 same-store sales guidance to a 7-8% decline, citing a cyclosporiasis outbreak and jalapeño recall. Founders adopted 10b5-1 plans to sell up to 4.9M shares. Operating losses widened despite a Spyce sale cash boost.
Key Events · Earnings and Guidance · SG
-
Same-Store Sales Plunge, Guidance Slashed
Q2 2026 same-store sales fell 6.2%, bringing H1 decline to 9.3%. Full-year guidance cut to a 7-8% drop from prior 2-4%, driven by a cyclosporiasis outbreak and jalapeño recall reducing consumer demand for fresh prepared foods.
-
Operating Losses Widen Despite Spyce Sale Gain
Q2 operating loss grew to $27.4M from $26.4M a year ago, as restaurant-level costs rose faster than revenue. H1 net income of $99.5M was entirely due to a $160.6M gain on the Spyce sale; excluding that, the business lost money.
-
Founders Adopt 10b5-1 Trading Plans
CEO Jonathan Neman adopted a plan to sell up to 1.8M shares, Chief Concept Officer Nicolas Jammet up to 1.5M shares, and Director Nathaniel Ru up to 1.6M shares. Plans were adopted in June 2026 and expire in September 2027.
-
Food Safety Risks Escalate
A new risk factor discloses a July 2026 multistate cyclosporiasis outbreak and an August 2026 supplier-initiated jalapeño recall. Both events are negatively impacting customer traffic and sales into Q3, with no timeline for recovery.
Analysis · SG · Trade & Services
Deepening operational struggles mark Sweetgreen's Q2 2026 results. Same-store sales fell 6.2% in the quarter and 9.3% for the first half, forcing management to cut full-year guidance to a 7-8% decline from the prior 2-4% drop. The company explicitly blames a July 2026 cyclosporiasis outbreak and an August jalapeño recall for reduced consumer demand, with the impact spilling into Q3. While the $100M cash infusion from the Spyce sale bolsters the balance sheet, the core business is losing money — operating loss widened to $27.4M in Q2. Adding to the overhang, the CEO, Chief Concept Officer, and a director each adopted 10b5-1 trading plans in June, authorizing sales of up to 4.9 million shares combined. The updated risk factor language signals that food safety headwinds are not yet contained.
At the time of this filing, SG was trading at $4.98 on NYSE in the Trade & Services sector, with a market capitalization of approximately $697.5M. The 52-week trading range was $4.49 to $12.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.